# MORPHEUS-panBC (atezolizumab): what clinicians are saying

> 7 statements from 4 sources (1 video, 3 posts), each linked to its source. Commentary checked Nov 20, 2026.

## Report

- Trial: A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)
- NCT ID: NCT03424005
- Registry: https://clinicaltrials.gov/study/NCT03424005
- Sponsor: Hoffmann-La Roche
- Phase: Phase 1/Phase 2
- Status: Recruiting
- Drugs tested: atezolizumab plus tocilizumab; atezolizumab plus sacituzumab govitecan; atezolizumab plus ipatasertib
- Indication: metastatic breast cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-11-20 UTC
- Last checked: 2026-11-20 UTC
- Release hash: 61b5095726d401d7aa480bfe00afea217559ef121cea566f92cb746e12df277c

## Counts

- Commentary sources screened: 12
- Sources cited by verified statements: 4
- Verified statements: 7
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 0
- Findings: 3
- Named people in screened sources (unnamed speakers and accounts not counted): 5
- Speakers cited: 5
- Cited speakers with a verified identity: 4
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 0
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 0

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

Speakers viewed MORPHEUS-panBC favorably for early activity, although one cautioned that the interim patient group was small and survival data were not yet mature. One speaker looked ahead to pembrolizumab data and a possible change in practice. The statements provide no safety interpretation or evidence that routine care changed.

## Findings (titles)

- F1. MORPHEUS: speakers note activity; one flags small n, immature survival
  - 4 statements from 4 speakers in 3 sources.
  - 4 of the 4 named speakers in this finding hold this view; 1 of them holds its caveat, “one flags small n, immature survival”.
  - No named clinician · accounts and unnamed speakers.
- F2. MORPHEUS: a speaker relays apparent benefit but flags short follow-up
  - 2 statements from 1 speaker in 1 source, a podcast or video.
  - The one named speaker in this finding holds this view; 1 of them holds its caveat, “flag short follow-up”.
  - No named clinician · accounts and unnamed speakers.

### Beyond the trial population

- F3. Pembrolizumab: a speaker looks ahead to data and possible practice change
  - 1 statement from 1 speaker in 1 source.
  - The one named speaker in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.

1 of the 3 findings and 1 of the 7 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 4 | 4 | 3 | 4 | 2 |
| F2 | 2 | 1 | 1 | 1 | 1 |
| F3 | 1 | 1 | 1 | 1 | 1 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 4 | 0 | 0 | 0 | 0 | 4 | 1 | 3 posts and articles |
| F2 | 1 | 0 | 0 | 1 | 0 | 2 | 1 | 1 podcast or video |
| F3 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 post or article |

### Trial dimensions

- Primary endpoint: Objective Response Rate (ORR): F1 (1 shared claims), F2 (1 shared claims)
- Secondary endpoints: F1 (1 shared claims), F2 (1 shared claims)
- Population and setting: F1 (2 shared claims)
- The comparison: F1 (1 shared claims), F2 (1 shared claims)
- Safety and tolerability: no finding draws on it directly
- Design and conduct: F1 (1 shared claims), F2 (1 shared claims)

## Abbreviations

- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- ORR: objective response rate

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 3 | Titles free |
| Detailed analysis | 5 sections | Paid |
| Verified statements with short source quotes and links | 7 | Paid |
| Who said each statement: the cited speakers | 5 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 0 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 4 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 8 | Free |
| Sources with links | 4 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 0 of the 5 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

7 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Objective Response Rate (ORR) | discussed | 2 | 2 |
| Secondary endpoints | discussed | 2 | 2 |
| Population and setting | discussed | 2 | 2 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 2 | 2 |
| Safety and tolerability | no commentary found | 0 | 0 |
| Design and conduct | discussed | 2 | 2 |
| Presentation salience and brief favorable reactions | discussed | 2 | 2 |
| Future pembrolizumab data and possible practice change | discussed | 1 | 1 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 2 statements · 29%** | | | |
| YouTube | 2 | 1 | 1 |
| **Posts · 5 statements · 71%** | | | |
| X threads | 5 | 3 | 11 |

- Screened window: 2023-05-11 to 2026-10-25
- Cited window: 2024-05-15 to 2024-05-20
- Retrieved: 2026-11-20

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)
- Registry: NCT03424005 (https://clinicaltrials.gov/study/NCT03424005)
- Study IDs: CO40115 · 2017-002038-21 · 2023-503629-20-00
- Sponsor: Hoffmann-La Roche
- Collaborators: Gilead Sciences, Pfizer
- Design: Phase 1/Phase 2 · interventional, randomized, parallel, phase1, phase2
- Status: Recruiting
- Enrollment: 1,132 (estimated)
- Start: 2018-03-30 (actual)
- Primary completion: 2030-09-30 (estimated)
- Primary endpoint: Objective Response Rate (ORR) (Baseline until disease progression or loss of clinical benefit (up to approximately 12 years))
- Intervention: Capecitabine (drug)
- Intervention: Atezolizumab (drug)
- Intervention: Ipatasertib (drug)
- Intervention: SGN-LIV1A (drug)
- Intervention: Bevacizumab (drug)
- Intervention: Chemotherapy (Gemcitabine + Carboplatin or Eribulin) (drug)
- Intervention: Selicrelumab (drug)
- Intervention: Tocilizumab (drug)
- Intervention: Nab-Paclitaxel (drug)
- Intervention: Sacituzumab Govitecan (drug)
- Intervention: Abemaciclib (drug)
- Intervention: Fulvestrant (drug)
- Intervention: Ribociclib (Dose #1) (drug)
- Intervention: Inavolisib (Dose #1) (drug)
- Intervention: Trastuzumab Deruxtecan (drug)
- Intervention: Ribociclib (Dose #2) (drug)
- Intervention: Letrozole (drug)
- Intervention: Inavolisib (Dose #2) (drug)
- Intervention: Empagliflozin (drug)
- Intervention: Palbociclib (drug)
- Intervention: Metformin (drug)
- Intervention: Atirmociclib (drug)
- Intervention: Giredestrant (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 7 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 51 sources about other trials or topics are not included.
- The sources reviewed for this edition are not a representative sample of HCP opinion; reposts do not add independent clinical assessments.
- Searches emphasized trial identifiers and names, so discussion using unnamed references or other variants may be missing.
- The favorable interpretations were qualified by a small interim patient group, immature survival and short follow-up; they should not be read as mature benefit–risk conclusions.
- No numerical comparative endpoint estimates, safety or tolerability interpretation, or documented change in routine care appears in the cited statements.
- No protocol was listed in the registry, and no publication for the exact trial was identified for this edition. This report describes public interpretations rather than an independent assessment of a full trial report.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-20 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-20 UTC. No changes.

## Offer

- Size: Focused · 7 verified statements · none from confirmed clinicians
- Not for sale: This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested. No order can be placed for it, by any route; a later edition that reaches the minimum is for sale at its normal price. Follow the change feed: https://www.erudio.com/reports/morpheus-panbc-nct03424005/feed.json
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=morpheus-panbc-nct03424005

## Cite

Erudio Health. MORPHEUS-panBC (NCT03424005): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 20, 2026. https://www.erudio.com/reports/morpheus-panbc-nct03424005

## Questions

### How much does the MORPHEUS-panBC report cost?

This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested.

### What does the MORPHEUS-panBC report cover?

7 statements from 4 sources (1 video, 3 posts), each linked to its source. Commentary checked Nov 20, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the MORPHEUS-panBC report?

Its preview, yes: get_report_card({ "slug": "morpheus-panbc-nct03424005" }) on https://mcp.erudio.com/free, with no sign-in. It cannot be ordered yet. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the MORPHEUS-panBC report?

Edition 1 (version 1.0.0), accepted Nov 20, 2026 UTC; last checked for new commentary Nov 20, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/morpheus-panbc-nct03424005.json
- Markdown: https://www.erudio.com/reports/morpheus-panbc-nct03424005.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/morpheus-panbc-nct03424005/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "morpheus-panbc-nct03424005"}`
